|Bid||21.69 x 100|
|Ask||21.76 x 200|
|Day's Range||21.47 - 21.93|
|52 Week Range||17.70 - 22.42|
|PE Ratio (TTM)||32.49|
|Earnings Date||Apr 30, 2018 - May 4, 2018|
|Forward Dividend & Yield||0.24 (1.12%)|
|1y Target Est||21.17|
Luminex Corporation (NASDAQ:LMNX) generated a below-average return on equity of 6.72% in the past 12 months, while its industry returned 10.71%. Though LMNX’s recent performance is underwhelming, it is usefulRead More...
AUSTIN, Texas , March 8, 2018 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that management will present at the Barclays Global Healthcare Conference to be held March 13-15, 2018, ...
Luminex Corp (NASDAQ:LMNX) files its latest 10-K with SEC for the fiscal year ended on December 31, 2017.
NEW YORK, Feb. 26, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Luminex ...
Luminex's (LMNX) extensive product line and rising revenues raise optimism. However, a challenging reimbursement scenario is likely to mar prospects.
On a per-share basis, the Austin, Texas-based company said it had a loss of 7 cents. Earnings, adjusted for pretax expenses, were 17 cents per share. The manufacturer of testing systems for biotechnology ...
AUSTIN, Texas , Feb. 12, 2018 /PRNewswire/ -- Luminex Corporation (NASDAQ:LMNX) today announced financial results for the fourth quarter and full-year 2017. Financial and operating highlights for the ...
AUSTIN, Texas , Feb. 6, 2018 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that management will present at the LEERINK Partners 7 th Annual Global Healthcare Conference to be held ...
AUSTIN, Texas , Jan. 24, 2018 /PRNewswire/ -- Luminex Corporation (Nasdaq:LMNX) (the "Company"), today announced that its board of directors declared a cash dividend for the first quarter of ...
How Is Accelerate Diagnostics Positioned at the Start of 2018? Accelerate Diagnostics’ (AXDX) Pheno System utilizes genotypic and phenotypic technology to identify infectious pathogens and perform antibiotic susceptibility tests (or AST), which determine if live bacterial or fungal cells are resistant or susceptible to a particular antimicrobial agent. The kit includes 140 assays for identification and susceptibility testing.
AUSTIN, Texas, Jan. 7, 2018 /PRNewswire/ -- Luminex Corporation (LMNX) today announced that it expects its revenues in the fourth quarter of 2017 to be approximately $78 million and to exceed $306 million for the full- year ended 2017. Luminex President and CEO, Homi Shamir, will present at the 36th Annual J.P. Morgan Healthcare Conference to be held at The Westin St. Francis hotel in San Francisco, CA on Thursday, January 11 at 10:00 a.m. Pacific time.
Abbott (ABT) appears to gain traction from the current integration and synergy achievement of St. Jude. Meanwhile, the company's recent closure of Alere takeover is another positive.
DexCom's (DXCM) collaborative agreements should bring in cash in the form of milestone payments and royalties, and help expand product portfolio.
Genomic Health's (GHDX) recent positive finds from a string of 10 trials on Oncotype DX Breast Recurrence Score test are likely to buoy investors' optimism.
Ecolab (ECL) continues to focus on investment in key businesses and bolt-on acquisitions to gain market traction and boost profits.